Binding Site Analysis of Potential Protease Inhibitors of COVID-19 Using AutoDock

Overview

Journal Virusdisease

Publisher Springer

Specialty Microbiology

Date 2020 May 5

PMID 32363219

Citations 35

Authors

Dipti Mothay

K V Ramesh

Affiliations

Soon will be listed here.

Abstract

Recent outbreak of COVID-19 caused by SARS-CoV-2 in December 2019 raised global health concerns. Re-purposing the available protease inhibitor drugs for immediate use in treatment in SARS-CoV-2 infections could improve the currently available clinical management. The current study, aims to predict theoretical structure for protease of COVID-19 and to explore further whether this protein can serve as a target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir, ritonavir and α-ketoamide. While the 3D structure of protease was predicted using SWISS MODEL server, molecular interaction studies between protein and ligands were performed using AutoDock software. The predicted protease model was reasonably good based on reports generated by different validation servers. The study further revealed that all the protease inhibitor drugs got docked with negative dock energy onto the target protein. Molecular interaction studies showed that protease structure had multiple active site residues for remdesivir, while for remaining ligands the structure had only one active site residue each. From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors.

Citing Articles

Computational and GC-MS screening of bioactive compounds from Thymus Vulgaris targeting mycolactone protein associated with Buruli ulcer.

Naveed M, Ali I, Aziz T, Saleem A, Rajpoot Z, Khaleel S Sci Rep. 2025; 15(1):131.

PMID: 39747211 PMC: 11696270. DOI: 10.1038/s41598-024-83908-0.

Functional characterization of a cold related flavanone 3-hydroxylase from Tetrastigma hemsleyanum: an in vitro, in silico and in vivo study.

Wu L, Tian J, Yu Y, Yuan L, Zhang Y, Wu H Biotechnol Lett. 2023; 45(11-12):1565-1578.

PMID: 37910279 DOI: 10.1007/s10529-023-03440-5.

Predictive value of serum human epididymis protein 4 for heart failure in patients with chronic kidney disease.

Dong C, Feng S, Ma H, Lei Y, Guo L, Sun Z Am J Transl Res. 2023; 15(9):5664-5673.

PMID: 37854237 PMC: 10579016.

Fluorinated derivatives of tetrahydroaltersolanol molecule on COVID-19, HIV, and HTLV protease by DFT and molecular docking approaches.

Azadparvar M, Kheirabadi M, Aliabad H J Mol Model. 2022; 28(11):350.

PMID: 36217060 PMC: 9550597. DOI: 10.1007/s00894-022-05340-3.

Prediction of the mechanism of action of catechin as superoxide anion antioxidants and natural antivirals for COVID-19 infection with study.

Zainuddin A, Hidayat I, Kurnia D, Ramadhanty Z, Padilah R J Adv Pharm Technol Res. 2022; 13(3):191-196.

PMID: 35935692 PMC: 9355057. DOI: 10.4103/japtr.japtr_67_22.

References

Sievers F, Wilm A, Dineen D, Gibson T, Karplus K, Li W . Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011; 7:539. PMC: 3261699. DOI: 10.1038/msb.2011.75. View

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

Schoeman D, Fielding B . Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1):69. PMC: 6537279. DOI: 10.1186/s12985-019-1182-0. View

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

Schwede T, Kopp J, Guex N, Peitsch M . SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003; 31(13):3381-5. PMC: 168927. DOI: 10.1093/nar/gkg520. View

Johansson M, Zoete V, Michielin O, Guex N . Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics. 2012; 13:173. PMC: 3436773. DOI: 10.1186/1471-2105-13-173. View

Cui J, Li F, Shi Z . Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2018; 17(3):181-192. PMC: 7097006. DOI: 10.1038/s41579-018-0118-9. View

Nukoolkarn V, Lee V, Malaisree M, Aruksakulwong O, Hannongbua S . Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008; 254(4):861-7. PMC: 7094092. DOI: 10.1016/j.jtbi.2008.07.030. View

Goodsell D, Olson A . Automated docking of substrates to proteins by simulated annealing. Proteins. 1990; 8(3):195-202. DOI: 10.1002/prot.340080302. View

10.

Hsieh L, Lin C, Su B, Jan T, Chen C, Wang C . Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res. 2010; 88(1):25-30. PMC: 7114315. DOI: 10.1016/j.antiviral.2010.06.010. View

11.

Li J, You Z, Wang Q, Zhou Z, Qiu Y, Luo R . The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020; 22(2):80-85. PMC: 7079563. DOI: 10.1016/j.micinf.2020.02.002. View

12.

Kim Y, Lovell S, Tiew K, Mandadapu S, Alliston K, Battaile K . Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012; 86(21):11754-62. PMC: 3486288. DOI: 10.1128/JVI.01348-12. View

13.

Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J . HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004; 318(3):719-25. PMC: 7111005. DOI: 10.1016/j.bbrc.2004.04.083. View

14.

Wang F, Chen C, Tan W, Yang K, Yang H . Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci Rep. 2016; 6:22677. PMC: 4780191. DOI: 10.1038/srep22677. View

15.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

16.

Eisenberg D, Luthy R, Bowie J . VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997; 277:396-404. DOI: 10.1016/s0076-6879(97)77022-8. View

17.

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

18.

Tahir Ul Qamar M, Alqahtani S, Alamri M, Chen L . Structural basis of SARS-CoV-2 3CL and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020; 10(4):313-319. PMC: 7156227. DOI: 10.1016/j.jpha.2020.03.009. View

19.

Chen Z, Fu J, Shu Q, Chen Y, Hua C, Li F . Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020; 16(3):240-246. PMC: 7091166. DOI: 10.1007/s12519-020-00345-5. View

20.

Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J . α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J Med Chem. 2020; 63(9):4562-4578. DOI: 10.1021/acs.jmedchem.9b01828. View